2001
DOI: 10.1042/cs1020099
|View full text |Cite
|
Sign up to set email alerts
|

Potential therapeutic uses for S-nitrosothiols

Abstract: The S-nitrosothiols (RSNOs) are thought to represent a circulating endogenous reservoir of nitric oxide (NO), and may have potential as donors of NO, distinct from currently used agents. They have the general formula RSNO, and naturally occurring examples include S-nitrosocysteine, S-nitrosoglutathione and S-nitrosoalbumin, in which R is an amino acid, polypeptide and protein respectively. RSNOs have anti-platelet properties, a theoretical role in the treatment of asthma and the potential to be used as agents … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
59
0
2

Year Published

2004
2004
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 76 publications
(61 citation statements)
references
References 54 publications
0
59
0
2
Order By: Relevance
“…Although there are many reports of possible therapeutic benefits of S-nitrosothiols in a variety of clinical situations, the therapeutic potential of many existing S-nitrosothiols is limited by their rapid NO release and poor distribution to the target site (Leopold and Loscalzo, 2000;Richardson and Benjamin, 2002). Therefore, the release rate of NO from S-nitrosothiols and its tissue distribution need to be well controlled to develop more effective NO delivery systems.…”
Section: Discussionmentioning
confidence: 99%
“…Although there are many reports of possible therapeutic benefits of S-nitrosothiols in a variety of clinical situations, the therapeutic potential of many existing S-nitrosothiols is limited by their rapid NO release and poor distribution to the target site (Leopold and Loscalzo, 2000;Richardson and Benjamin, 2002). Therefore, the release rate of NO from S-nitrosothiols and its tissue distribution need to be well controlled to develop more effective NO delivery systems.…”
Section: Discussionmentioning
confidence: 99%
“…As potent systemic vasodilators and platelet inhibitors, RSNOs have been evaluated in the treatment of various cardiovascular complications, including thrombosis, vasospasm, preeclampsia, and ischemia/reperfusion injury. [12][13][14] Furthermore, because of their bronchodilating properties and the fact that the airway level of RSNOs is reduced in asthma and cystic fibrosis patients, RSNOs are considered as promising therapeutics for pulmonary conditions. 41,42 Finally, RSNOs may be used as antiviral and antimicrobial agents, because they inhibit viral protease enzymes and possess a strong bacteriostatic effect.…”
Section: Vasoregulation With Natural Thiols and Pfc: A Safe Alternatimentioning
confidence: 99%
“…[3][4][5][6][7] Because RSNOs are relatively stable and can release NO when required on reaction with various reducing agents, 8,9 they may serve as a buffering system that magnifies the range of NO action along the vascular tree. 10,11 Although the pharmacological potential of RSNO is well appreciated, [12][13][14] the role of plasma NO and the mechanism of endogenous RSNO formation under physiological conditions are a source of considerable debate. 15 The apparent limitation for plasma NO to exert its biological function is the constant presence of abundant hemoglobin (10 mmol/L) from red blood cells that converts NO into inactive metabolites at near-diffusion-limited rates.…”
mentioning
confidence: 99%
“…Attention has been focused recently on the role of S-nitrosylation (Foster et al, 2003) by S-nitrosothiol (RSNO) including S-nitrosoglutathione (GSNO) in storage and transport of NO (Hogg, 2002;Janero, 2000;Richardson, 2002). S-Nitrosoglutathione is a physiological metabolite of glutathione (GSH) and NO (Megson, 2000;Schrammel et al, 2003), and is involved in several pharmacological activities (Chiueh, 2002) and signaling (Choi et al, 2000;Gu et al, 2002;Lane et al, 2001;Stamler et al, 1997).…”
Section: Introductionmentioning
confidence: 99%